> ## Content Index > Fetch the complete content index at: https://www.moatmarginresearch.com/llms.txt > Use this file to discover other available public pages before exploring further. # Alkem Laboratories Moat Analysis: Score & Risks - URL: https://www.moatmarginresearch.com/alkem-laboratories-moat/ - Published: 2026-08-02T13:13:28.000Z - Updated: 2026-08-22T05:14:25.000Z - Author: A K Karthikeyan - Tags: First-pass note, Coverage Moat Note · First-pass ## Alkem Laboratories Ltd. A first-pass moat teardown of Alkem Laboratories Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it. **Moat & Margin**2 Aug 2026 First-pass · \~4 min 5.04 / 10 NARROWBrand-led First-pass narrow read — primary edge in Network Effects. Provisional, single-pass evidence. Provisional score · subject to modification based on new evidence Alkem Laboratories Ltd. scores **5.04** on MoatSCORE 6.0 — a narrow moat in Pharma. This is a **first-pass note**: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued. The teardown ## Seven dimensions of moat Ordered by contribution. Each dimension carries a verified filing quote, graded **\[M\]** mechanism or **\[O\]** outcome. D1Network Effects6 M · Mechanism✓ Verified verbatim “Behind every success are our people. With over 21,000+ employees, including 12,500+ medical representatives, Alkem's culture remains rooted in empowerment, agility, and shared purpose.” **Alkem Laboratories Ltd.** · Annual Report · p.12 D5Intangible Assets6 O · Outcome✓ Verified verbatim “We have outperformed IPM in six key focused therapies: Gastro-intestinal grew by \~1.8X, VMN \~1.6X, Pain \~1.7X, Anti-Diabetic \~1.4X, Respiratory \~1.6X and Derma \~2.0X.” **Alkem Laboratories Ltd.** · Investor Presentation · p.3 2 quotes extracted here — not one mechanism-class. The evidence is outcome-only. D3Cost Advantage4.8 M · Mechanism✓ Verified verbatim “By combining a North America-based delivery engine with an India-led R&D and cost leadership, Enzene is building a differentiated model that offers global biotech firms the best of both worlds.” **Alkem Laboratories Ltd.** · Annual Report · p.10 D4Price Discretion4.8 No narrative receipt surfaced — this dimension is scored on the quantitative record. D2Switching Costs4.5 M · Mechanism✓ Verified verbatim “What sets Enzene apart is not just technical strength, but also its growing global client base across human health and animal health, including pharma partners in the US, Europe, and India.” **Alkem Laboratories Ltd.** · Annual Report · p.33 D6Efficient Scale4.5 O · Outcome✓ Verified verbatim “Talent density across R&D, regulatory, quality, and precision manufacturing” **Alkem Laboratories Ltd.** · Investor Presentation · p.6 2 quotes extracted here — not one mechanism-class. The evidence is outcome-only. D7Counter-PositioningExcluded— Excluded for this archetype. D8Ungoverned RiskUnscored · Layer 2.5 D8 rating: **ADEQUATE**. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed. The barrier gate ## The barrier gate — first-pass Replication — can a rival copy it?6.0 How hard it is for a rival to copy the edge (first-pass estimate). Bypass — can a rival route around it?6.0 How easily a rival can route around the edge (first-pass estimate). Effective barrier 6.0 — clears the gate. First-pass estimate. What would change our mind 1. **Deep two-pass review.** This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read. 2. **The barrier gate.** A firmer replication or bypass estimate is the most likely thing to shift the band. 3. **Adverse events.** Any governance, regulatory or funding shock captured in D8 could re-rate the fade window. First-pass note — provisional single-pass MoatSCORE 6.0 read, not the full deep dive. Educational research, not investment advice; no buy/sell recommendation, no price target. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser. **Where this note fits.** This company is one of **113 Indian companies** we have scored for moat durability — 88 narrow, 25 narrow-trending-wide, none wide. The full ranked read: [Wide-Moat Stocks in India: We Scored 113 Companies and Found None](https://www.moatmarginresearch.com/wide-moat-stocks-india/). Every score, dimension by dimension, is free in the [Moat Screener](https://www.moatmarginresearch.com/moat-screener/).